Urinary polycyclic aromatic hydrocarbon metabolites and hyperlipidemia: NHANES 2007-2016.
Cross-sectional study
Hyperlipidemia
Polycyclic aromatic hydrocarbons
Urinary PAH metabolites
Journal
Lipids in health and disease
ISSN: 1476-511X
Titre abrégé: Lipids Health Dis
Pays: England
ID NLM: 101147696
Informations de publication
Date de publication:
27 May 2024
27 May 2024
Historique:
received:
28
03
2024
accepted:
17
05
2024
medline:
28
5
2024
pubmed:
28
5
2024
entrez:
27
5
2024
Statut:
epublish
Résumé
The relationships between urinary polycyclic aromatic hydrocarbon (PAH) metabolites and hyperlipidemia have not been thoroughly studied. The primary goal of this research focused on investigating the linkage between PAH metabolite concentrations in urine and hyperlipidemia prevalence within US adults. A cross-sectional analysis was conducted using data from the 2007-2016 National Health and Nutrition Examination Survey (NHANES). Logistic regression models were used to assess correlations between urinary PAH metabolite levels and the risk of hyperlipidemia, while restricted cubic spline models were used to examine dose‒response relationships. Subgroup and interaction analyses were performed to further elucidate these associations. Weighted quantile sum (WQS) regression analyzed the cumulative impact of various urinary PAH metabolites on hyperlipidemia risk. This study included 7,030 participants. Notably, individuals in the highest quintile of urinary PAH metabolite concentrations exhibited a significantly elevated prevalence of hyperlipidemia, even after comprehensive adjustments (odds ratio [OR]: 1.33, 95% confidence interval [CI]: 1.01-1.75). Moreover, elevated levels of 1-hydroxyphenanthrene and 2-hydroxynaphthalene in the fourth quintile and 2-hydroxyfluorene in the third, fourth, and fifth quintiles demonstrated positive correlations with the prevalence of hyperlipidemia. These associations persisted across subgroup analyses. Additionally, a positive correlation between the urinary PAH metabolite mixture and hyperlipidemia (positive model: OR = 1.04, 95% CI: 1.00-1.09) was observed in the WQS model, and 2-hydroxynaphthalene showed the most substantial contribution. The cross-sectional analysis identified a significant correlation between urinary PAH metabolite and hyperlipidemia prevalence within the US demographic, with 2-hydroxynaphthalene being the predominant influencer. These findings underscore the need to mitigate PAH exposure as a preventive measure for hyperlipidemia.
Sections du résumé
BACKGROUND
BACKGROUND
The relationships between urinary polycyclic aromatic hydrocarbon (PAH) metabolites and hyperlipidemia have not been thoroughly studied. The primary goal of this research focused on investigating the linkage between PAH metabolite concentrations in urine and hyperlipidemia prevalence within US adults.
METHODS
METHODS
A cross-sectional analysis was conducted using data from the 2007-2016 National Health and Nutrition Examination Survey (NHANES). Logistic regression models were used to assess correlations between urinary PAH metabolite levels and the risk of hyperlipidemia, while restricted cubic spline models were used to examine dose‒response relationships. Subgroup and interaction analyses were performed to further elucidate these associations. Weighted quantile sum (WQS) regression analyzed the cumulative impact of various urinary PAH metabolites on hyperlipidemia risk.
RESULTS
RESULTS
This study included 7,030 participants. Notably, individuals in the highest quintile of urinary PAH metabolite concentrations exhibited a significantly elevated prevalence of hyperlipidemia, even after comprehensive adjustments (odds ratio [OR]: 1.33, 95% confidence interval [CI]: 1.01-1.75). Moreover, elevated levels of 1-hydroxyphenanthrene and 2-hydroxynaphthalene in the fourth quintile and 2-hydroxyfluorene in the third, fourth, and fifth quintiles demonstrated positive correlations with the prevalence of hyperlipidemia. These associations persisted across subgroup analyses. Additionally, a positive correlation between the urinary PAH metabolite mixture and hyperlipidemia (positive model: OR = 1.04, 95% CI: 1.00-1.09) was observed in the WQS model, and 2-hydroxynaphthalene showed the most substantial contribution.
CONCLUSION
CONCLUSIONS
The cross-sectional analysis identified a significant correlation between urinary PAH metabolite and hyperlipidemia prevalence within the US demographic, with 2-hydroxynaphthalene being the predominant influencer. These findings underscore the need to mitigate PAH exposure as a preventive measure for hyperlipidemia.
Identifiants
pubmed: 38802874
doi: 10.1186/s12944-024-02153-6
pii: 10.1186/s12944-024-02153-6
doi:
Substances chimiques
Polycyclic Aromatic Hydrocarbons
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
160Subventions
Organisme : The Student Innovation Ability Enhancement Project under the First-class Professional Construction Project at Guangzhou Medical University
ID : 02-408-240603131128
Organisme : The Medical Scientific Research Foundation of Guangdong Province
ID : Nos. A2022125
Informations de copyright
© 2024. The Author(s).
Références
Laufs U, Parhofer KG, Ginsberg HN, Hegele RA. Clinical review on triglycerides. Eur Heart J. 2020;41(1):99–c109.
pubmed: 31764986
doi: 10.1093/eurheartj/ehz785
Su X, Peng H, Chen X, Wu X, Wang B. Hyperlipidemia and hypothyroidism. Clin Chim Acta. 2022;527:61–70.
pubmed: 35038435
doi: 10.1016/j.cca.2022.01.006
Pirillo A, Casula M, Olmastroni E, Norata GD, Catapano AL. Global epidemiology of dyslipidaemias. Nat Rev Cardiol. 2021;18(10):689–700.
pubmed: 33833450
doi: 10.1038/s41569-021-00541-4
Gaggini M, Gorini F, Vassalle C. Lipids in Atherosclerosis: Pathophysiology and the Role of Calculated Lipid Indices in Assessing Cardiovascular Risk in Patients with Hyperlipidemia. Int J Mol Sci. 2022;24(1):75.
pubmed: 36613514
pmcid: 9820080
doi: 10.3390/ijms24010075
Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, et al. Heart Disease and Stroke Statistics-2022 update: a Report from the American Heart Association. Circulation. 2022;145(8):e153–639.
pubmed: 35078371
doi: 10.1161/CIR.0000000000001052
Ma J, Hao X, Nie X, Yang S, Zhou M, Wang D, et al. Longitudinal relationships of polycyclic aromatic hydrocarbons exposure and genetic susceptibility with blood lipid profiles. Environ Int. 2022;164:107259.
pubmed: 35500530
doi: 10.1016/j.envint.2022.107259
Mallah MA, Changxing L, Mallah MA, Noreen S, Liu Y, Saeed M, et al. Polycyclic aromatic hydrocarbon and its effects on human health: an overeview. Chemosphere. 2022;296:133948.
pubmed: 35151703
doi: 10.1016/j.chemosphere.2022.133948
Sun S, Mao W, Tao S, Zou X, Tian S, Qian S, et al. Polycyclic Aromatic Hydrocarbons and the risk of kidney stones in US adults: an exposure-response analysis of NHANES 2007–2012. Int J Gen Med. 2021;14:2665–76.
pubmed: 34188522
pmcid: 8232959
doi: 10.2147/IJGM.S319779
Yang X, Xue Q, Wen Y, Huang Y, Wang Y, Mahai G, et al. Environmental polycyclic aromatic hydrocarbon exposure in relation to metabolic syndrome in US adults. Sci Total Environ. 2022;840:156673.
pubmed: 35700788
doi: 10.1016/j.scitotenv.2022.156673
Wang F, Wang Y, Wang Y, Jia T, Chang L, Ding J, et al. Urinary polycyclic aromatic hydrocarbon metabolites were associated with hypertension in US adults: data from NHANES 2009–2016. Environ Sci Pollut Res Int. 2022;29(53):80491–501.
pubmed: 35716300
doi: 10.1007/s11356-022-21391-8
Huang X, Deng X, Li W, Liu S, Chen Y, Yang B, et al. Internal exposure levels of polycyclic aromatic hydrocarbons in children and adolescents: a systematic review and meta-analysis. Environ Health Prev Med. 2019;24(1):50.
pubmed: 31351468
pmcid: 6661086
doi: 10.1186/s12199-019-0805-9
Mallah MA, Changxing L, Mallah MA, Naveed M, Liu Y, Noreen S, et al. Association of urinary polycyclic aromatic hydrocarbon metabolites and cardiovascular disease among US population: a cross-sectional study. Environ Res. 2022;209:112775.
pubmed: 35065070
doi: 10.1016/j.envres.2022.112775
Alshaarawy O, Zhu M, Ducatman AM, Conway B, Andrew ME. Urinary polycyclic aromatic hydrocarbon biomarkers and diabetes mellitus. Occup Environ Med. 2014;71(6):437–41.
pubmed: 24638887
doi: 10.1136/oemed-2013-101987
White AJ, Bradshaw PT, Herring AH, Teitelbaum SL, Beyea J, Stellman SD, et al. Exposure to multiple sources of polycyclic aromatic hydrocarbons and breast cancer incidence. Environ Int. 2016;89–90:185–92.
pubmed: 26878284
pmcid: 4818720
doi: 10.1016/j.envint.2016.02.009
Stading R, Gastelum G, Chu C, Jiang W, Moorthy B. Molecular mechanisms of pulmonary carcinogenesis by polycyclic aromatic hydrocarbons (PAHs): implications for human lung cancer. Semin Cancer Biol. 2021;76:3–16.
pubmed: 34242741
pmcid: 8728691
doi: 10.1016/j.semcancer.2021.07.001
Ma J, Zhou Y, Liu Y, Xiao L, Cen X, Li W, et al. Association between urinary polycyclic aromatic hydrocarbon metabolites and dyslipidemias in the Chinese general population: a cross-sectional study. Environ Pollut. 2019;245:89–97.
pubmed: 30415036
doi: 10.1016/j.envpol.2018.10.134
Jin Y, Miao W, Lin X, Wu T, Shen H, Chen S, et al. Sub-chronically exposing mice to a polycyclic aromatic hydrocarbon increases lipid accumulation in their livers. Environ Toxicol Pharmacol. 2014;38(2):353–63.
pubmed: 25124514
doi: 10.1016/j.etap.2014.07.014
Li F, Xiang B, Jin Y, Li C, Li J, Ren S, et al. Dysregulation of lipid metabolism induced by airway exposure to polycyclic aromatic hydrocarbons in C57BL/6 mice. Environ Pollut. 2019;245:986–93.
pubmed: 30682755
doi: 10.1016/j.envpol.2018.11.049
Hu H, Kan H, Kearney GD, Xu X. Associations between exposure to polycyclic aromatic hydrocarbons and glucose homeostasis as well as metabolic syndrome in nondiabetic adults. Sci Total Environ. 2015;505:56–64.
pubmed: 25310882
doi: 10.1016/j.scitotenv.2014.09.085
Alshaarawy O, Elbaz HA, Andrew ME. The association of urinary polycyclic aromatic hydrocarbon biomarkers and cardiovascular disease in the US population. Environ Int. 2016;89–90:174–8.
pubmed: 26878282
pmcid: 4818691
doi: 10.1016/j.envint.2016.02.006
Mallah MA, Basnet TB, Ali M, Xie F, Li X, Feng F, et al. Association between urinary polycyclic aromatic hydrocarbon metabolites and diabetes mellitus among the US population: a cross-sectional study. Int Health. 2023;15(2):161–70.
pubmed: 35751578
doi: 10.1093/inthealth/ihac029
Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–421.
doi: 10.1161/circ.106.25.3143
Han Y, Jiang X, Qin Y, Zhao Y, Zhang G, Liu C. A cross-sectional study exploring the relationship between the dietary inflammatory index and hyperlipidemia based on the National Health and Nutrition Examination Survey (2005–2018). Lipids Health Dis. 2023;22(1):140.
pubmed: 37653500
pmcid: 10470145
doi: 10.1186/s12944-023-01908-x
Zhang Y, Liu W, Zhang W, Cheng R, Tan A, Shen S, et al. Association between blood lead levels and hyperlipidemiais: results from the NHANES (1999–2018). Front Public Health. 2022;10:981749.
pubmed: 36159291
pmcid: 9500574
doi: 10.3389/fpubh.2022.981749
Ranjbar M, Rotondi MA, Ardern CI, Kuk JL. Urinary biomarkers of polycyclic aromatic hydrocarbons are associated with cardiometabolic health risk. PLoS ONE. 2015;10(9):e0137536.
pubmed: 26340343
pmcid: 4560466
doi: 10.1371/journal.pone.0137536
Stallings-Smith S, Mease A, Johnson TM, Arikawa AY. Exploring the association between polycyclic aromatic hydrocarbons and diabetes among adults in the United States. Environ Res. 2018;166:588–94.
pubmed: 29982146
doi: 10.1016/j.envres.2018.06.041
Carrico C, Gennings C, Wheeler DC, Factor-Litvak P. Characterization of Weighted Quantile Sum Regression for highly correlated data in a risk analysis setting. J Agric Biol Environ Stat. 2015;20(1):100–20.
pubmed: 30505142
doi: 10.1007/s13253-014-0180-3
Karr S. Epidemiology and management of hyperlipidemia. Am J Manag Care. 2017;23(9 Suppl):S139–48.
pubmed: 28978219
Acharya N, Gautam B, Subbiah S, Rogge MM, Anderson TA, Gao W. Polycyclic aromatic hydrocarbons in breast milk of obese vs normal women: infant exposure and risk assessment. Sci Total Environ. 2019;668:658–67.
pubmed: 30856574
doi: 10.1016/j.scitotenv.2019.02.381
Sousa S, Paíga P, Pestana D, Faria G, Delerue-Matos C, Ramalhosa MJ, et al. Evaluating the impact of polycyclic aromatic hydrocarbon bioaccumulation in adipose tissue of obese women. Chemosphere. 2024;353:141673.
pubmed: 38462176
doi: 10.1016/j.chemosphere.2024.141673
Wang Y, Zhu L, James-Todd T, Sun Q. Urinary polycyclic aromatic hydrocarbon excretion and regional body fat distribution: evidence from the U.S. National Health and Nutrition Examination Survey 2001–2016. Environ Health. 2022;21(1):75.
pubmed: 35945606
pmcid: 9364531
doi: 10.1186/s12940-022-00890-8
Alhamdow A, Lindh C, Albin M, Gustavsson P, Tinnerberg H, Broberg K. Early markers of cardiovascular disease are associated with occupational exposure to polycyclic aromatic hydrocarbons. Sci Rep. 2017;7(1):9426.
pubmed: 28842704
pmcid: 5573323
doi: 10.1038/s41598-017-09956-x
Hýžd’alová M, Pivnicka J, Zapletal O, Vázquez-Gómez G, Matthews J, Neca J, et al. Aryl Hydrocarbon receptor-dependent metabolism plays a significant role in Estrogen-Like effects of Polycyclic Aromatic hydrocarbons on Cell Proliferation. Toxicol Sci. 2018;165(2):447–61.
pubmed: 30137621
pmcid: 6154273
doi: 10.1093/toxsci/kfy153
Sun H, Shen OX, Xu XL, Song L, Wang XR. Carbaryl, 1-naphthol and 2-naphthol inhibit the beta-1 thyroid hormone receptor-mediated transcription in vitro. Toxicology. 2008;249(2–3):238–42.
pubmed: 18584933
doi: 10.1016/j.tox.2008.05.008
Schultz TW, Sinks GD. Xenoestrogenic gene expression: structural features of active polycyclic aromatic hydrocarbons. Environ Toxicol Chem. 2002;21(4):783–6.
pubmed: 11951952
doi: 10.1002/etc.5620210414
Irigaray P, Ogier V, Jacquenet S, Notet V, Sibille P, Méjean L, et al. Benzo[a]pyrene impairs beta-adrenergic stimulation of adipose tissue lipolysis and causes weight gain in mice. A novel molecular mechanism of toxicity for a common food pollutant. Febs j. 2006;273(7):1362–72.
pubmed: 16689925
doi: 10.1111/j.1742-4658.2006.05159.x
Bright A, Li F, Movahed M, Shi H, Xue B. Chronic Exposure to Low-Molecular-Weight Polycyclic Aromatic Hydrocarbons Promotes Lipid Accumulation and Metabolic Inflammation. Biomolecules. 2023;13(2):196.
pubmed: 36830566
pmcid: 9953192
doi: 10.3390/biom13020196
Mlyczyńska E, Bongrani A, Rame C, Węgiel M, Maślanka A, Major P, et al. Concentration of Polycyclic Aromatic Hydrocarbons (PAHs) in Human Serum and Adipose Tissues and Stimulatory Effect of Naphthalene in Adipogenesis in 3T3-L1 Cells. Int J Mol Sci. 2023;24(2):1455.
pubmed: 36674971
pmcid: 9861916
doi: 10.3390/ijms24021455
Vogel CFA, Van Winkle LS, Esser C, Haarmann-Stemmann T. The aryl hydrocarbon receptor as a target of environmental stressors - implications for pollution mediated stress and inflammatory responses. Redox Biol. 2020;34:101530.
pubmed: 32354640
pmcid: 7327980
doi: 10.1016/j.redox.2020.101530
Yang Q, Qiu X, Li R, Ma J, Li K, Li G. Polycyclic aromatic hydrocarbon (PAH) exposure and oxidative stress for a rural population from the North China Plain. Environ Sci Pollut Res Int. 2015;22(3):1760–9.
pubmed: 25015715
doi: 10.1007/s11356-014-3284-y
Pulliero A, Godschalk R, Andreassi MG, Curfs D, Van Schooten FJ, Izzotti A. Environmental carcinogens and mutational pathways in atherosclerosis. Int J Hyg Environ Health. 2015;218(3):293–312.
pubmed: 25704189
doi: 10.1016/j.ijheh.2015.01.007
Cosselman KE, Navas-Acien A, Kaufman JD. Environmental factors in cardiovascular disease. Nat Rev Cardiol. 2015;12(11):627–42.
pubmed: 26461967
doi: 10.1038/nrcardio.2015.152
Zhao X, Niu Y, Zhao XL, Ruan HJ, Xiang Y, Wang LY, et al. Associations between serum TNF-α, IL-6, hs-CRP and GLMD in obese children and adolescents: a cross-sectional study. Diabetes Metab Syndr Obes. 2023;16:3915–23.
pubmed: 38077482
pmcid: 10700039
doi: 10.2147/DMSO.S434482
Patel R, Palit SP, Rathwa N, Ramachandran AV, Begum R. Genetic variants of tumor necrosis factor-α and its levels: a correlation with dyslipidemia and type 2 diabetes susceptibility. Clin Nutr. 2019;38(3):1414–22.
pubmed: 29980311
doi: 10.1016/j.clnu.2018.06.962
Zhou S, Li X, Dai Y, Guo C, Peng R, Qin P, et al. Association between polycyclic aromatic hydrocarbon exposure and blood lipid levels: the indirect effects of inflammation and oxidative stress. Environ Sci Pollut Res Int. 2023;30(59):123148–63.
pubmed: 37979116
doi: 10.1007/s11356-023-31020-7
Umer A, Kelley GA, Cottrell LE, Giacobbi P Jr., Innes KE, Lilly CL. Childhood obesity and adult cardiovascular disease risk factors: a systematic review with meta-analysis. BMC Public Health. 2017;17(1):683.
pubmed: 28851330
pmcid: 5575877
doi: 10.1186/s12889-017-4691-z